Spots Global Cancer Trial Database for Study of SyB C-1101 in Patients With Myelodysplastic Syndrome
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of SyB C-1101 in Patients With Myelodysplastic Syndrome
Official Title: Multi-center, Open-label, Phase I Study of SyB C-1101 in Patients With Myelodysplastic Syndrome
Study ID: NCT03495167
Conditions
Interventions
Study Description
Brief Summary: To assess tolerability of SyB C-1101 when administered orally BID for 21 days followed by a 7-day observation period in patients with recurrent/relapsed or refractory myelodysplastic syndrome in order to determine a recommended dose (RD). To assess safety, efficacy and pharmacokinetics.
Detailed Description:
Keywords
Eligibility
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Research Site, Nagoya, Aichi, Japan
Research Site, Maebashi, Gunma, Japan
Research Site, Sapporo, Hokkaido, Japan
Research Site, Kobe, Hyogo, Japan
Research Site, Kurashiki, Okayama, Japan
Research Site, Shinagawa, Tokyo, Japan
Research Site, Fukuoka, , Japan
Research Site, Kumamoto, , Japan
Research Site, Kyoto, , Japan
Contact Details
Name: Katsuhisa Goto
Affiliation: SymBio Pharmaceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
